To include your compound in the COVID-19 Resource Center, submit it here.
Epizyme began an open-label, international Phase II trial to evaluate 800 mg oral tazemetostat twice daily in about 90 adult patients. The
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury